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Background. An imbalance between the generation of reac-
tive oxygen species (ROS) and antioxidant defense mechanisms
has been suggested to play an important role in podocyte injury
in nephrotic syndrome. Experimental nephrotic syndrome in-
duced by injection of puromycin aminonucleoside (PAN) into
rats is a well-established model of nephrotic syndrome, and can
be largely prevented by pretreatment with antioxidant enzymes
(AOE), suggesting that podocyte injury may be mediated by
ROS.
Methods. To test the hypothesis that PAN-induced podocyte
injury is modulated in part by podocyte antioxidant defenses,
we analyzed AOE activities, lipid peroxidation products, and
relative ROS levels in podocytes using our recently reported in
vitro model of PAN-induced podocyte injury.
Results. PAN treatment induced early increases in both
podocyte hydrogen peroxide and superoxide and later increases
in lipid peroxidation products. Compared to baseline activities,
PAN also induced significant changes in the major cellular AOE
activities (maximum increases of 151% for catalase, 134% for
superoxide dismutase, and 220% for glutathione peroxidase vs.
time-matched controls). These changes largely preceded the de-
velopment of extensive podocyte process retraction and actin
filament disruption, which was maximal at 7 days.
Conclusion. These results demonstrate that (1) PAN treat-
ment induces significant early changes in podocyte ROS, (2)
podocytes can mount an antioxidant defense against oxidant
stress, and (3) this protective response is initiated prior to the
development of extensive oxidant-induced podocyte structural
injury. These findings suggest that enhancement of podocyte
AOE activities represent a potential therapeutic target to pro-
tect from or ameliorate podocyte injury during nephrotic syn-
drome.
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Nephrotic syndrome is a common kidney disease
in adults, and among the most common kidney dis-
eases seen in children, with an estimated incidence of
two to seven new cases annually per 100,000 children
[1]. Nephrotic syndrome is characterized by morphologic
changes in the visceral epithelial cells (podocytes) of the
kidney glomerulus. The podocyte cell body and primary
cell processes are suspended in the urinary space of the
glomerulus, and finer secondary and tertiary processes
attach the cell to the underlying glomerular basement
membrane and interdigitate with processes from adja-
cent podocytes. The gaps between these interdigitating
processes are spanned by a specialized cell-cell junction,
the slit diaphragm. During development of nephrotic
syndrome, this elaborate morphology of the podocyte
is dramatically altered, resulting in changes that include
cell swelling, retraction, and effacement (spreading) of
foot processes, vacuole formation, formation of occlud-
ing junctions with displacement or disruption of the
slit diaphragms, and foot process detachment from the
glomerular basement membrane [2–6]. The effacement of
foot processes correlates closely with the development of
leakage of protein across the glomerular filtration barrier
resulting in proteinuria [3, 5, 7], and is the characteristic
ultrastructural finding for nephrotic syndrome.
Recently, positional cloning studies have identified sev-
eral gene mutations responsible for certain rare forms
of nephrotic syndrome, and mouse gene knockout stud-
ies have identified a number of podocyte proteins whose
functional absence leads to the development of nephrotic
syndrome. These studies have clearly established the im-
portance of specific podocyte proteins, especially proteins
shown to reside in the slit diaphragm, for glomerular
function [reviewed in 8, 9]. However, far fewer data are
available regarding the molecular mechanisms that are
responsible for the changes in podocyte structure and
function in the majority of patients with idiopathic and
acquired forms of nephrotic syndrome.
One potential mechanism for these changes has been
suggested by numerous studies in animal models of
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nephrotic syndrome that have indirectly linked oxidant
injury of podocytes with the subsequent development of
foot process effacement and nephrotic syndrome. The
most commonly used experimental model of nephrotic
syndrome is the injection of puromycin aminonucleoside
(PAN) into rats, a treatment that leads to development
of foot process effacement and proteinuria within 7 to
10 days [6, 10]. The development of nephrotic syndrome
has been associated with an early and transient induc-
tion of glomerular reactive oxygen species (ROS) [11],
a decrease in glomerular antioxidant enzyme (AOE) ac-
tivity [12], and accumulation products of oxidative dam-
age to membranes (lipid peroxides) in the renal cortex
[13], glomeruli [14, 15], and urine [13–15]. Conversely,
pretreatment of animals with ROS scavengers [16–18]
or the iron chelator deferoxamine (which prevents iron-
catalyzed production of ROS) [19] prior to induction
of experimental nephrotic syndrome resulted in either
marked attenuation or complete prevention of both clin-
ical and histologic disease. One major weakness of all of
these studies, however, is that there have never been any
measurements of either ROS or AOE activities or pro-
tein levels directly within podocytes, the glomerular cell
most critically involved in the pathogenesis of nephrotic
syndrome.
Based on these findings, we hypothesized that oxidant-
induced podocyte injury may be a critical final common
pathway for the development of nephrotic syndrome,
and more specifically that PAN-induced podocyte injury
is mediated by ROS and modulated by podocyte an-
tioxidant defenses. To test this hypothesis, we designed
studies to specifically measure, in podocytes, the activi-
ties and protein expression of the major cellular AOE,
catalase (CAT), superoxide dismutase (SOD), and glu-
tathione peroxidase (GPx), as well as measuring the
relative amounts of the major cellular ROS, hydrogen
peroxide and superoxide, and a product of lipid per-
oxidation, malondialdehyde (MDA), produced within
podocytes both before and following PAN-induced
podocyte injury.
METHODS
Cell culture
A clonal cell line of conditionally-immortalized murine
podocytes (MPC-5) isolated from the “Immortomouse”
was the kind gift of Dr. Peter Mundel [20]. Podocyte cells
were grown and induced to differentiate as previously
described [21]. All cultured podocytes used in this study
were allowed to differentiate without subcultivation for 8
to 10 days prior to treatment. Cells were seeded in 75 cm2
flasks (1 × 106 cells/flask), 6-well culture dishes (3 × 105
cells/well), or 96-well culture dishes (1 × 103 cells/well)
for differentiation and treatment. Treatment consisted of
the addition of PAN (5 lg/mL from 1000× aqueous stock
solution) or vehicle (sterile water) in fresh medium, and
culture for various time periods in the presence of PAN.
Cell viability assay
Podocytes differentiated in 96-well culture dishes
were sham- or PAN-treated for specific times, and
cell viability was assayed by 3-[4,5] dimethylthiazol-2,5-
diphenyltetrazolium bromide (MTT) assay as previously
described [22]. Briefly, 50 lL of 50 mg/mL MTT was
added to wells containing treated cells under 200 lL of
medium, and cells were incubated 4 hours under culture
conditions. Medium containing MTT was removed, and
150 lL of dimethyl sulfoxide (DMSO) was added to all
wells, and plates were read immediately at 570 nm. Wells
containing no cells (but containing medium and MTT
over the incubation period) were used to blank the plate
reader.
Preparation of podocyte extracts
After treatments, medium was removed and cells were
washed with warm phosphate-buffered saline (PBS).
Cells were then collected by addition of trypsin solu-
tion (Gibco-BRL, Rockville, MD, USA), brief incuba-
tion, and centrifugation at 2000g for 5 minutes. The num-
ber of cells in suspensions were determined by counting
cells in an aliquot in a hemocytometer prior to centrifu-
gation. Cells were washed with PBS, centrifuged again,
and lysed on ice with agitation for 15 minutes in cold
hypo-osmotic buffer [50 mmol/L potassium phosphate,
0.1 mmol/L ethylenediaminetetraacetic acid (EDTA),
and 0.1% Triton X-100, pH 7.8]. The amount of lysis
buffer used was adjusted to a ratio of 5 × 106 cells/mL
buffer. Extracts were then centrifuged at 12,000g for 15
minutes at 4◦C. Supernatants were stored at −70◦C.
ROS assays
Podocytes differentiated in 6-well dishes were treated
with vehicle alone or with 5 lg/mL of PAN for 1, 3, 5,
7, or 12 hours, or for 1, 3, 5, or 7 days. Cells were then
loaded with either 2 lmol/L 5-(and 6-)chloromethyl-2′,7′-
dichlorodihydrofluorescein diacetate (CM-H2DCFDA)
or 3 lmol/L dihydroethidium (DHE) dissolved in
medium without serum for 30 minutes. These compounds
are relatively specific for determination of hydrogen per-
oxide [oxidation of CM-H2DCFDA to carboxydichloro-
fluorescein (CDCF)] or superoxide (oxidation of DHE to
ethidium), respectively [23, 24]. Cells were subsequently
washed with Hank’s balanced salt solution (HBSS) buffer
(10 mmol/L HEPES, 150 mmol/L NaCl, 5 mm KCl,
1 mmol/L MgCl2, and 1.8 mmol/L CaCl2) and fluores-
cence was measured at 520 nm after excitation at 485 nm
(CDCF), at 612 nm after excitation at 518 nm (ethidium
bound to DNA), or at 430 nm after excitation at 410 nm
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(DHE) with an Ascent Fluoroskan plate reader (MTX
Lab, Inc., Vienna, VA, USA).
Thiobarbituric acid assay of podocyte MDA
Podocytes differentiated in 6-well dishes were treated
with vehicle alone or with 5 lg/mL of PAN for 0, 1,
3, 5, or 7 days. Cells were washed with ice-cold PBS
and then scraped into 500 lL per well of ice-cold RIPA
buffer [50 mmol/L Tris-Cl, pH 7.4, 150 mmol/L NaCl, 1
mmol/L EDTA, 1 mmol/L phenylmethylsulfonyl fluoride
(PMSF), 5 lg/mL each aprotinin and leupeptin, 0.1% Tri-
ton X-100, 1% sodium deoxycholate, and 0.1% sodium
dodecyl sulfate (SDS)] and homogenized by sonication
four times for 5 seconds each on ice. Homogenates were
centrifuged at 14,000g for 20 minutes, an aliquot of the
supernatant was removed for protein assay (see below),
and trichloroacetic acid was added to the remaining su-
pernatant to a final concentration of 6% (wt/vol). Af-
ter a 15-minute incubation on ice, protein precipitates
were pelleted by centrifugation at 3000g for 15 minutes
at 4◦C. To determine the concentration of MDA in su-
pernatants, an equal volume of 0.67% (wt/vol) thiobarbi-
turic acid was added to an aliquot of each supernatant
and samples were held in a boiling water bath for 10
minutes, cooled, and absorbance read at 530 nm. MDA
concentrations were calculated from a standard curve of
various concentrations of 1,1,3,3-tetramethoxypropane
subjected to the same assay.
AOE activity assays
Cu-Zn- and Mn-SOD activities were measured
by oxidation of 5,6,6a,11b-tetrahydro-3,9,10-trihydroxy-
benzo[c]fluorene in aqueous alkaline solution to yield
a chromophore with maximum absorbance at 525 nm
(Bioxytech SOD-525TM) (Oxis Research, Portland OR,
USA). The SOD activity was expressed in units (U)
defined as the activity that doubled the auto-oxidation
rate of a control blank containing 5,6,6a,11b-tetrahydro-
3,9,10-trihydroxybenzo[c]fluorene.
CAT activity was measured by consumption of hydro-
gen peroxide, as determined by absorbance at 240 nm.
CAT activity was expressed in units (U) defined as the k
value of the enzyme reaction at 25◦C where:
k = (1/(t2 − t1))(ln(OD1/OD2))
where OD = absorbance of H2O2 and t = time in seconds.
GPx activity was measured by the conversion of the re-
duced form of nicotinamide adenine dinucleotide phos-
phate (NADPH) to NADP+ by glutathione reductase,
the enzyme that reduces the glutathione oxidized by
GPx, as determined by the decrease in absorbance of the
substrate, NADPH, at 340 nm (Glutathione Peroxidase
Assay Kit) (Cayman Chemical, Ann Arbor, MI, USA).
GPx activity was expressed in units (U) defined as the
amount of GPx required to oxidize 1.0 nmol of NADPH
to NADP+ at 25◦C/min/mL.
Phase-contrast and phalloidin-labeled fluorescence
microscopy
Cells grown on coverslips and treated were washed
briefly in warm PBS and fixed in 3.7% paraformaldehyde
in PBS, pH 7.4, for 30 minutes. Cells were lysed by addi-
tion of an equal volume of 0.5% Triton X-100 in PBS to
the fixation solution for 5 minutes. After removal of the
fixative, cells were washed with 0.05% Tween-20 in PBS
(T-PBS) and incubated with Texas Red-conjugated phal-
loidin (Molecular Probes, Eugene, OR, USA) diluted
1:250 in T-PBS for 30 minutes. Coverslips were washed
and mounted in ProLong Antifade (Molecular Probes)
according to the manufacturer’s instructions.
Phase-contrast and fluorescence microscopy was per-
formed using an inverted fluorescence microscope
(DMIRE-2) (Leica Microsystems, Inc., Bannockburn, IL,
USA) and images were collected with a monochrome
cooled charged coupling device (CCD) camera (Retiga
1300C; Retiga, Millersville, MD, USA) using OpenLab
3.1.4 software (Improvision, Inc., Lexington, MA, USA).
Images were adjusted for contrast and gain in Adobe Pho-
toshop version 7.0.1.
Protein assay
The Bio-Rad DC Protein Assay (Bio-Rad, Hercules,
CA, USA) microplate protocol was used to quantify to-
tal protein in samples. Lysis and SDS-polyacrylamide gel
electrophoresis (PAGE) sample buffers were used to pre-
pare albumin protein standards to normalize for the effect
of buffer components on the assay results.
Statistics
Results were analyzed for statistical significance using
Statview version 4.57 software (Abacus Concepts, Berke-
ley, CA, USA) by the unpaired, two-tailed t test. Com-
parisons with P values < 0.05 were considered significant,
and P values < 0.01 were separately noted.
RESULTS
Podocyte viability decreases after PAN
The viability of cultured, differentiated, murine
podocytes treated with 5 lg/mL PAN for various times
or vehicle for various times was measured by MTT assay.
Podocyte viability after PAN treatment was not signifi-
cantly different from vehicle-treated, time-matched con-
trols except after 7 days of treatment, when absorbance
in PAN-treated samples was 70 ± 8% of control values
(Fig. 1).
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Fig. 1. Podocyte viability decreases after puromycin aminonucleoside
(PAN) treatment. Results of absorbance measurements at 570 nm,
normalized for background, after 3-[4, 5] dimethylthiazol-2,5-diphenyl-
tetrazolium bromide (MTT) assay of cultured podocytes treated with
5.0 lg/mL PAN for 1, 3, 5, or 7 days. Podocyte viability at 7 days after
treatment was significantly decreased by PAN treatment compared to
time-matched controls (N = 8; v ± SEM). ∗P < 0.05 vs. time-matched
controls.
PAN induces podocyte process retraction and actin
filament disruption
Cultured podocytes prior to treatment displayed a
characteristic flattened phenotype with numerous cell
processes (Fig. 2A), and prominent central actin stress
fibers (Fig. 2B). Treatment of podocytes with 5.0 lg/mL
PAN resulted in a progressive retraction of processes by
5 days after treatment (Fig. 2G) and subsequent detach-
ment of some podocytes from the underlying substrate.
Initial disruption of the central actin stress fibers was first
detectable after 1 day of PAN treatment (Fig. 2D), and
by 7 days after treatment actin stress fibers were almost
entirely absent (Fig. 2J).
PAN treatment induces increases in both podocyte
hydrogen peroxide and superoxide
Fluorescence was measured in podocytes treated with
PAN for various periods and then loaded with the cell-
permeant fluorescent dyes DHE and CM-H2DCFDA.
When DHE is oxidized to ethidium in the cytoplasm it
can enter the nucleus and intercalate with cellular DNA,
resulting in a shift from blue fluorescence (DHE) to
red (ethidium). The acetoxymethyl ester groups of CM-
H2DCFDA are removed by intracellular esterases, and
intracellular ROS oxidize this compound to CDCF, which
is more fluorescent (oxidation) and less able to cross the
cell plasma membrane (de-esterification). Increases in
the ratio of ethidium to DHE fluorescence and in flu-
orescein fluorescence derived from CM-H2DCFDA are
thus measures of increases in ROS, more specifically of
increases in cellular hydrogen peroxide (CDCF) and su-
peroxide (ethidium) [24].
A significant increase in the mean fluorescein fluores-
cence in cells treated with PAN and subsequently loaded
with CM-H2DCFDA was only observed at 3 hours after
PAN treatment, and the magnitude of this change was
relatively small (127% of t = 0 value) (Fig. 3). This result
indicates that hydrogen peroxide generation was only
transiently and modestly increased in podocytes in
response to PAN treatment. No significant changes
in hydrogen peroxide in PAN-treated podocytes were
detected (compared to time-matched controls) at later
time points (1, 3, 5, or 7 days after PAN treatment) (data
not shown).
In contrast, an increase in the ratio of mean ethidium to
DHE fluorescence was observed at all time points tested,
although this change was only statistically significant at
7 and 12 hours after PAN treatment (546% and 551%
of t = 0 value, respectively) (Fig. 4). The fluorescence
observed in cells treated with PAN remained elevated for
at least 12 hours, indicating that the increase in the rate
of superoxide generation in podocytes, unlike the modest
and transient increase in hydrogen peroxide, was more
persistent. However, no significant changes in superoxide
in PAN-treated podocytes were detected (compared to
time-matched controls) at later time points (1, 3, 5, or 7
days after PAN treatment) (data not shown).
PAN treatment induces increases in podocyte MDA
The concentration of MDA was measured by thiobar-
bituric acid assay in deproteinated extracts of vehicle
alone and PAN-treated podocytes at 1, 3, 5, and 7 days af-
ter treatment. By 5 days after PAN treatment, the amount
of MDA normalized to the quantity of total cellular pro-
tein had increased significantly to 2.42 ± 0.26 nmol/lg
protein, and increased further by 7 d after treatment to
5.71 ± 1.14 nmol/lg protein (509% and 400% of time-
matched, vehicle-treated control values, respectively, see
Figure 5). These results demonstrate that PAN treatment
significantly increased the amount of a product of lipid
peroxidation (MDA) in cultured podocytes.
PAN treatment induces podocyte AOE activities
The baseline activities of the three major cellular AOE
(SOD, CAT, and GPx) were measured in cultured, dif-
ferentiated, murine podocytes (Table 1). Measurable
amounts of all three enzymes were detected.
The amount of CAT activity in sham-treated control
cells did not change significantly from its mean baseline
value at any time point tested, although there was a trend
toward decreased activity with increasing time after sham
treatment (Fig. 6). In contrast, by 3 days after treatment
with 5 lg/mL PAN, CAT activity increased significantly to
35.2±2.4 (×±SEM) mU/500 k podocytes (151% of time-
matched controls) (P < 0.01), and remained significantly
increased over the remaining 4-day treatment period
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Fig. 2. Puromycin aminonucleoside (PAN) induces podocyte process retraction and actin filament disruption. Phase-contrast (A, C, E, G, and I)
and fluorescence (B, D, F, H, and J) micrographs of cultured podocytes are shown following treatment for 0 (A and B), 1 (C and D), 3 (E and F), 5
(G and H), or 7 days (I and J) with 5 lg/mL PAN. Podocytes retracted and lost processes by 5 d of treatment, while actin filament disruption could
be detected as early as 1 day after addition of PAN.
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Fig. 3. Puromycin aminonucleoside (PAN) treatment induces an in-
crease in podocyte hydrogen peroxide. The results of fluorescence
measurements of carboxydichlorofluorescein (CDCF) at 520 nm af-
ter excitation at 485 nm of cultured podocytes treated with 5.0 lg/mL
PAN for various times and a t = 0 control and then loaded with 5-
(and 6-)chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate (CM-
H2DCFDA) for 30 minutes. PAN treatment ( ) for 3 hours induced a
modest and transient increase in fluorescence compared to cells that
did not receive PAN treatment () (N = 3; v ± SEM). ∗P < 0.05 vs.
t = 0.
(Fig. 6). The greatest increase in CAT activity (197% of
time-matched controls) (P < 0.01) was observed at 7 days
after PAN treatment.
The amount of SOD activity in sham-treated control
cells increased significantly (approximately 140% of t =
0 controls) (P < 0.05) to a mean value of approximately
50 U/500 k podocytes at 5 and 7 days after sham treat-
ment (Fig. 7). Compared to these values, treatment with
PAN induced a significant increase in podocyte SOD ac-
tivity to 66.7 ± 5.9 (SE) U/500 k podocytes (134% of
30
20
10
0R
at
io
 o
f e
th
id
iu
m
/D
HE
 fl
uo
re
sc
en
ce
0 1 3 5 7 12
Treatment period, hours
* *
Fig. 4. Puromycin aminonucleoside (PAN) treatment induces an in-
crease in podocyte superoxide. The ratio of fluorescence measurements
at 612 nm after excitation at 518 nm (ethidium) and at 430 nm after
excitation at 410 nm [dihydroethidium (DHE)] of cultured podocytes
treated with 5.0 lg/mL PAN for various times and a t = 0 control and
then loaded with DHE for 30 minutes. PAN treatment ( ) for 7 and 12
hours induced a significant increase in the ratio of ethidium to DHE
fluorescence compared to cells that did not receive PAN treatment ()
(N = 3; v ± SEM). ∗P < 0.05 vs. t = 0.
time-matched controls (P < 0.05) only at 7 days after
treatment, and this increase was also the largest detected
(Fig. 7).
The amount of GPx activity in sham-treated control
cells increased significantly (188% of time-matched con-
trols) (P < 0.05) at 1 day from its mean baseline value
to 48.0 ± 2.4 U/500 k podocytes, but was not differ-
ent from the day 0 value at any other time point tested
(Fig. 8). In response to PAN treatment, GPx activity in-
creased significantly (220% of time-matched controls)
(P < 0.01) at day 3 of treatment to 62.7 ± 4.1 U/500 k
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Fig. 5. Puromycin aminonucleoside (PAN) treatment induces an in-
crease in podocyte malondialdehyde (MDA). The amounts of MDA
normalized to total protein of cultured podocytes treated with vehicle
alone or 5.0 lg/mL PAN for various times. Treatment with PAN for both
5 and 7 days induced a significant increase in podocyte MDA compared
to cells treated with vehicle alone (N = 5; v ± SEM). ∗∗P < 0.01 vs.
time-matched controls.
Table 1. Baseline antioxidant enzyme activities of differentiated
podocytes
Enzyme Activity/mg proteina Activity/500 k podocytesb
SOD 47.3 ± 6.2 U 35.7 ± 3.8 U
CAT 35.6 ± 3.7 mU 25.2 ± 4.7 mU
GPx 34.2 ± 6.7 U 25.5 ± 5.3 U
Abbreviations are: SOD, Mn- and Cu-Zn-superoxide dismutase; CAT,
catalase; GPx, glutathione peroxidase.
aActivity normalized to total protein content (N = 8, v ± SD); bActivity
normalized to podocyte cell number (N = 8, v ± SD).
podocytes, but was not different from time-matched con-
trols at any other time points tested.
Together these results reveal that all three major cel-
lular AOE have detectable activities in untreated cul-
tured podocytes. In addition, the activity of each of these
AOE increased following PAN-induced ROS generation
in these cells, although the amount of increase in AOE
activity and the time course of induction varied between
different enzymes after PAN exposure.
DISCUSSION
There is abundant indirect evidence suggesting that ox-
idant injury to podocytes may have an important role
in the development of the structural and functional al-
terations that occur in podocytes during nephrotic syn-
drome. Most of the data on AOE activities, however,
have been derived from measurements of glomerular
and renal cortical samples [11, 25], permitting only in-
direct measurements of the AOE capacity of podocytes
to protect themselves from oxidant injury. In the current
study we report for the first time the direct measure-
ment of the activities of the three major cellular AOE
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Fig. 6. Puromycin aminonucleoside (PAN) treatment induces
podocyte catalase (CAT) activity. The results of CAT enzyme activity
assays in cultured podocytes treated with vehicle alone or with 5.0
lg/mL PAN for various times and a t = 0 control. PAN treatment in-
duced a significant increase in CAT activity compared to time-matched
sham-treated controls at 3, 5, and 7 days after PAN treatment. Enzyme
activity is expressed as k value (N = 7; v ± SEM). ∗P < 0.05; ∗∗P <
0.01 vs. time-matched control.
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Fig. 7. Puromycin aminonucleoside (PAN) treatment induces
podocyte superoxide dismutase (SOD) activity. The results of SOD
enzyme activity assays in cultured podocytes treated with vehicle alone
or with 5.0 lg/mL PAN for 1, 3, 5, or 7 days and a t = 0 control. PAN
treatment induced a significant increase in SOD activity only after 7
days of treatment compared to time-matched controls (N = 8; v ±
SEM). ∗P < 0.05 vs. time-matched control.
in cultured murine podocytes, and that podocyte injury
by PAN results in induction of podocyte ROS as well as
induction of podocyte AOE activities. While the timing
and extent of AOE induction was variable, induction of a
protective antioxidant response was initiated prior to the
development of extensive podocyte structural and actin
cytoskeletal injury. These findings suggest that enhance-
ment of podocyte AOE activities represent a potential
therapeutic target to protect from or ameliorate podocyte
injury during nephrotic syndrome.
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Fig. 8. Puromycin aminonucleoside (PAN) treatment induces
podocyte glutathione peroxidase (GPx) activity. The results of GPx
enzyme activity assays in cultured podocytes treated with vehicle alone
or with 5.0 lg/mL PAN for 1, 3, 5, and 7 days and a t = 0 control. PAN
treatment induced a significant increase in GPx activity compared to
time-matched controls only at 3 days after PAN treatment (N = 8; v ±
SEM). ∗∗P < 0.01 vs. time-matched control.
Injection of PAN into rats is a well-described model
system for the induction of experimental nephrotic syn-
drome [5, 26]. A number of reports have indirectly linked
PAN-induced nephrosis with oxidant injury of podocytes,
including detection of increased amounts of hydroperox-
ides in rat glomeruli after PAN injection [27–29], hydro-
gen peroxide generation in rat glomeruli in response to
PAN that could be blocked by inhibitors of cytochrome
P450 enzymes [30], and increases in glomerular lipid
peroxidation products after PAN treatment [14, 31]. In-
creased lipid peroxidation has also been measured in
glomeruli from humans with congenital nephrotic syn-
drome of the Finnish type [32]. Further evidence in
support of this potential mechanism includes studies
demonstrating that treatments commonly used to treat
nephrotic syndrome in humans, such as glucocorticoids
and other immunosuppressants, can increase glomerular
AOE and protect against PAN-induced injury [12, 14],
studies showing that AOE or antioxidants can amelio-
rate the effects of PAN [28, 29, 33, 34] and that inhibition
of AOE exacerbates PAN nephrosis [35]. A metabo-
lite of PAN has also previously been shown to be con-
verted by glomeruli to hypoxanthine, a component of
the xanthine/hypoxanthine pathway for the production
of superoxide radicals [36]. However, this report also
demonstrated that PAN itself, as well as other metabo-
lites of PAN that were not converted to hypoxanthine,
were equally toxic to cultured podocytes. These reports
together provide strong indirect evidence that the PAN-
induced injury to podocytes resulting in experimental
nephrotic syndrome is mediated by ROS, but they do
not clearly define either the mechanism or cell of origin
of ROS generation in PAN nephrosis.
In contrast to these prior studies, in the present stud-
ies we observed, specifically in podocytes, significant in-
creases in fluorescence from oxidized metabolites of both
CM-H2DCFDA (a measure of cellular hydrogen perox-
ide) and DHE (a measure of cellular superoxide), as well
as significant increases in the amount of MDA (a measure
of lipid peroxidation) and the activities of the three ma-
jor cellular AOE in response to PAN-induced injury. The
increases in fluorescence from the conversion of DHE
to ethidium, primarily due to superoxide, were greater
in magnitude and more persistent than the modest and
transient induction of fluorescence derived from the ox-
idation of CM-H2DCFDA (see Figs. 3 and 4), which is
consistent with the previous results suggesting that PAN
is converted to hypoxanthine, resulting in generation of
superoxide. Although significant changes in either DHE
and CM-H2DCFDA in PAN-treated podocytes were only
detected at times less than 24 hours after PAN treat-
ment, the significant increases in the amount of MDA
(a product of lipid peroxidation) measured 5 and 7 days
after PAN treatment (see Fig. 5) demonstrated that PAN-
induced generation of ROS continued throughout the 7-
day treatment period. Comparably elevated MDA levels
(2.93 nmol MDA/mg protein, 230% to 330% of con-
trols) have previously been detected in glomeruli of PAN-
treated rats [37], and increases in MDA have also been
demonstrated in glomeruli of patients with congenital
nephrotic syndrome of the Finnish type [32] and in red
blood cells from patients with a variety of glomerular
diseases. Our inability to detect the generation of ROS
during a 30-minute incubation with ROS indicator flu-
orophores in the period from 1 to 7 days after PAN
treatment suggests that the rate of ROS generation in
podocytes exposed to PAN decreases after 12 hours but
apparently remains high enough to lead to cumulative
ROS-induced injury (increased MDA after 5 and 7 days
of PAN treatment). Since the increases in CAT and GPx
activities were most evident at 3 to 5 days after exposure
to PAN, while the increase in SOD activity was only sig-
nificant at 7 days after PAN treatment, the generation of
hydrogen peroxide, possibly from superoxide, is likely to
be the molecule that induces the most dramatic cellular
defense response. It is notable that while the maximal
induction of CAT and SOD activities occurred at a time
that cultured podocytes had already developed clearly al-
tered morphology (Fig. 2G and I) and disruption of actin
filaments (Fig. 2H and J), the initial increases in podocyte
CAT and GPx activities were observed prior to extensive
changes in the morphology of the majority of cultured
podocytes, and when only modest actin filament disrup-
tion was observed (Fig. 2E and F). These results are in
contrast to a previously observed decrease in GPx and
CAT activities in isolated rat glomeruli at 9 days after in-
duction of PAN nephrosis, where no detectable increases
in AOE were seen despite both an early (15 minutes) and
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late (9 days) induction of ROS by PAN in these glomeruli
[38]. Similarly, glomerular GPx levels have been reported
to be decreased in both patients with focal segmental
glomerulosclerosis and in rats with PAN-induced sclero-
sis [39]. This discrepancy between our results and earlier
studies may indicate that isolated podocytes are capable
of responding to oxidant stress by induction of AOE ac-
tivities, but that the prior measurements of total glomeru-
lar AOE activities, in which other glomerular cells may
have had decreased AOE activities, masked the AOE in-
duction specifically within the podocytes. Alternatively,
podocytes in vivo may be unable to effectively increase
AOE activities in the functional milieu of the glomerulus
where, in contrast to culture conditions, continuous blood
perfusion and filtration are both occurring.
Our studies identified notably different podocyte AOE
activities than have previously been estimated from anal-
yses of intact glomeruli. For example, assuming there are
approximately 300 podocytes per glomerulus [40], our
measured mean CAT activity of 25 mU/500 k podocytes
correlates to a derived value of 15 mU of podocyte CAT
activity/1000 glomeruli, a value markedly higher than the
previously reported 1 to 2 mU/1000 rat glomeruli [25].
Similarly, the SOD and GPx activities measured in cul-
tured murine podocytes (21 U SOD and 15 U GPx per
300 k cultured podocytes) were considerably higher than
the values described previously in rat glomeruli (3 U SOD
and 4 U per 1000 rat glomeruli) [25]. There are several
potential explanations for these discrepancies, including
loss of glomerular AOE activities during the prolonged
(>1 hour) procedures required for glomerular isolation
compared to the immediate isolation of proteins from
cultured cells, the presence of factors in glomeruli that
may interfere with enzyme assays, blunting of podocyte
AOE findings when analyzed as part of entire glomeru-
lar preparations, and species variation of AOE activities
between mice and rats. Our use of an SOD enzyme assay
kit using a new substrate also makes comparison of our
findings with previous literature difficult, as the definition
of enzyme activity units is based on relative differences
between sample based oxidation and auto-oxidation of
this substrate rather than reduction in cytochrome C
absorbance in a xanthine/xanthine oxidase coupled sys-
tem as previously reported [25]. Finally, it has also been
reported that the CAT activity of primary cultures of
mesangial cells increases after prolonged periods in cul-
ture [25], suggesting that the increased AOE activities
found in conditionally immortalized murine podocytes
may be a result of culture conditions.
Together our findings support the hypothesis that PAN
acts via ROS to induce experimental nephrotic syndrome,
and that podocytes express active AOE and can re-
spond to oxidant injury by induction of CAT, SOD, and
GPx activities. Furthermore, the induction of AOE ac-
tivity prior to the development of extensive changes in
podocyte morphology and actin cytoskeleton suggests
that enhancement of podocyte AOE activities might rep-
resent a potential therapeutic target to protect from or
ameliorate podocyte injury during nephrotic syndrome.
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